Technology & Software Global On demand · 24-48h

Global Molecular Pathology Services Market Strategic Research Report

Global Molecular Pathology Services Market Strategic Researc…
$3,500 USD
Market Research Reports
Strategic Research Report
Global Molecular Pathology Services Market
$1582025
7.8%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Solid Tumor Molecular Pathology Services, Hematologic Malignancy Molecular Pathology Services, Hereditary Disease Molecular Pathology Services, Infectious Disease Molecular Testing Services, Rare Disease Molecular Pathology Services, Others

By Application: Hospitals and Medical Centers, Independent Clinical Laboratories, Academic and Research Institutes, Biopharmaceutical Companies, Others

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Quest Diagnostics, Labcorp, Sonic Healthcare, NeoGenomics, Foundation Medicine, Caris Life Sciences, Tempus, Guardant Health, Exact Sciences, Eurofins, Unilabs

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 117 pages
Market size 2025
$158
Million USD
Forecast CAGR
7.8%
2025-2032
Forecast 2032
$267.3
Projected
Regiones
5
Asia Pacific · Latin America · MEA · Europe · North America

Vista general

Scope of the Report

The global Molecular Pathology Services market size is predicted to grow from US$ 158 million in 2025 to US$ 272 million in 2032; it is expected to grow at a CAGR of 7.8% from 2026 to 2032.

Molecular Pathology Services refer to laboratory and consultative pathology services that use DNA-, RNA-, and biomarker-based testing methods to support disease diagnosis, classification, prognosis, therapy selection, and treatment monitoring. These services commonly integrate PCR, NGS, FISH, sequencing, liquid biopsy, pathology interpretation, and clinical reporting into a unified diagnostic workflow.

Global key Molecular Pathology Services players cover Quest Diagnostics, Labcorp, Sonic Healthcare, NeoGenomics, Foundation Medicine, etc.

This report presents a comprehensive overview of the global Molecular Pathology Services market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Solid Tumor Molecular Pathology Services
  • Hematologic Malignancy Molecular Pathology Services
  • Hereditary Disease Molecular Pathology Services
  • Infectious Disease Molecular Testing Services
  • Rare Disease Molecular Pathology Services
  • Others

Segment by Service Content

  • Single-Gene Testing Services
  • Targeted Panel Testing Services
  • Comprehensive Genomic Profiling Services
  • Companion Diagnostic Support Services
  • Pathology Consultation and Interpretation Services
  • Others

Segment by Application

  • Hospitals and Medical Centers
  • Independent Clinical Laboratories
  • Academic and Research Institutes
  • Biopharmaceutical Companies
  • Others

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Molecular Pathology Services market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Hospitals and Medical Centers, Independent Clinical Laboratories, Academic and Research Institutes evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Molecular Pathology Services Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 7.8%
Regional growth momentum
Market share by segment
Key metrics
Base value
$158
2025
Forecast
$267.3
2032
CAGR
7.8%
2025–2032
Regiones
5
global
Key companies
Quest DiagnosticsLabcorpSonic HealthcareNeoGenomicsFoundation MedicineCaris Life SciencesTempusGuardant Health
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Solid Tumor Molecular Pathology ServicesHematologic Malignancy Molecular Pathology ServicesHereditary Disease Molecular Pathology ServicesInfectious Disease Molecular Testing ServicesRare Disease Molecular Pathology ServicesOthers
By Application
Hospitals and Medical CentersIndependent Clinical LaboratoriesAcademic and Research InstitutesBiopharmaceutical CompaniesOthers

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Solid Tumor Molecular Pathology Services
  • 3.1.3 Hematologic Malignancy Molecular Pathology Services
  • 3.1.4 Hereditary Disease Molecular Pathology Services
  • 3.1.5 Infectious Disease Molecular Testing Services
  • 3.1.6 Rare Disease Molecular Pathology Services
  • 3.1.7 Others
  • 3.1.8 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Hospitals and Medical Centers
  • 4.1.3 Independent Clinical Laboratories
  • 4.1.4 Academic and Research Institutes
  • 4.1.5 Biopharmaceutical Companies
  • 4.1.6 Others
  • 4.1.7 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Quest Diagnostics
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Labcorp
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 Sonic Healthcare
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 NeoGenomics
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 Foundation Medicine
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Caris Life Sciences
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Tempus
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 Guardant Health
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 Exact Sciences
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 Eurofins
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Unilabs
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

How big is the global Molecular Pathology Services market?
The global Molecular Pathology Services market is estimated at US$ 158 million in 2025 (base year) and is projected to reach US$ 272 million by 2032.
How fast is the Molecular Pathology Services market expected to grow?
The market is expected to grow at a CAGR of 7.8% from 2026 to 2032, expanding from US$ 158 million in 2025 to US$ 272 million in 2032, roughly 1.7 times its base-year value.
What does the Molecular Pathology Services market cover?
Molecular Pathology Services refer to laboratory and consultative pathology services that use DNA-, RNA-, and biomarker-based testing methods to support disease diagnosis, classification, prognosis, therapy selection, and treatment monitoring. These services commonly integrate PCR, NGS, FISH, sequencing, liquid biopsy, pathology interpretation, and clinical reporting into a unified diagnostic workflow.
What are the main segments of the Molecular Pathology Services market by type?
By type, the market is segmented into Solid Tumor Molecular Pathology Services, Hematologic Malignancy Molecular Pathology Services, Hereditary Disease Molecular Pathology Services, Infectious Disease Molecular Testing Services, Rare Disease Molecular Pathology Services and Others.
Which applications drive demand in the Molecular Pathology Services market?
Key applications covered include Hospitals and Medical Centers, Independent Clinical Laboratories, Academic and Research Institutes, Biopharmaceutical Companies and Others.
Who are the key players in the Molecular Pathology Services market?
Key players profiled include Quest Diagnostics, Labcorp, Sonic Healthcare, NeoGenomics, Foundation Medicine, Caris Life Sciences, Tempus and Guardant Health, among 11 companies covered in total.
Which regions and countries are covered for Molecular Pathology Services?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
Who should buy the Molecular Pathology Services market report?
The report is intended for manufacturers and solution providers, distributors and end users in Hospitals and Medical Centers, Independent Clinical Laboratories and Academic and Research Institutes, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Molecular Pathology Services market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

All data sources are cited within the report. View our full research methodology →
Select a license
from 3.500,00 US$
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.